Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci George G. Zhanel * , Daryl J. Hoban , and James A. Karlowsky Departments of Clinical Microbiology and Medicine, Health Sciences Centre and Faculties of Medicine and Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada ABSTRACT The activity of nitrofurantoin was tested against 300 isolates of Enterococcus faecium , Enterococcus faecalis , and Enterococcus gallinarum . No isolates tested were resistant to nitrofurantoin (MIC, ≥128 μg/ml), including vancomycin-resistant E. faecium isolates with vanA - and vanB -positive genotypes and vancomycin-resistant E. gallinarum isolates. We conclude that nitrofurantoin may provide effective treatment of urinary tract infections caused by vancomycin-resistant enterococci. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antimicrobial Agents and Chemotherapy American Society For Microbiology

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci

Download PDF

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci

Zhanel, George G.; Hoban, Daryl J.; Karlowsky, James A.
Antimicrobial Agents and Chemotherapy , Volume 45 (1): 324 – Jan 1, 2001

Abstract

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci George G. Zhanel * , Daryl J. Hoban , and James A. Karlowsky Departments of Clinical Microbiology and Medicine, Health Sciences Centre and Faculties of Medicine and Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada ABSTRACT The activity of nitrofurantoin was tested against 300 isolates of Enterococcus faecium , Enterococcus faecalis , and Enterococcus gallinarum . No isolates tested were resistant to nitrofurantoin (MIC, ≥128 μg/ml), including vancomycin-resistant E. faecium isolates with vanA - and vanB -positive genotypes and vancomycin-resistant E. gallinarum isolates. We conclude that nitrofurantoin may provide effective treatment of urinary tract infections caused by vancomycin-resistant enterococci.

Loading next page...
 
/lp/american-society-for-microbiology/nitrofurantoin-is-active-against-vancomycin-resistant-enterococci-0ZxKZzRhV4

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2001 by the American society for Microbiology.
ISSN
0066-4804
eISSN
1098-6596
DOI
10.1128/AAC.45.1.324-326.2001
pmid
11120989
Publisher site
See Article on Publisher Site

Abstract

Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci George G. Zhanel * , Daryl J. Hoban , and James A. Karlowsky Departments of Clinical Microbiology and Medicine, Health Sciences Centre and Faculties of Medicine and Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada ABSTRACT The activity of nitrofurantoin was tested against 300 isolates of Enterococcus faecium , Enterococcus faecalis , and Enterococcus gallinarum . No isolates tested were resistant to nitrofurantoin (MIC, ≥128 μg/ml), including vancomycin-resistant E. faecium isolates with vanA - and vanB -positive genotypes and vancomycin-resistant E. gallinarum isolates. We conclude that nitrofurantoin may provide effective treatment of urinary tract infections caused by vancomycin-resistant enterococci.

Journal

Antimicrobial Agents and Chemotherapy – American Society For Microbiology

Published: Jan 1, 2001

References

  • Enterococcal infections of the urinary tract.
    Childs
  • The pharmacokinetics of nitrofurantoin and its related bioavailability.
    Conklin
  • Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.
    Dutka-Malen
  • Identification of Enterococcus species isolated from human infections by a conventional test scheme.
    Facklam
  • Enterococci and vancomycin resistance.
    French
  • Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones
  • Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
    Jones
  • Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals.
    Karlowsky
  • Treatment of vancomycin resistant Enterococcus faecium infections.
    Lai
  • Vancomycin resistant enterococci.
    Moellering